Observational Study of Delayed Nausea and Vomiting

Completed

Conditions studied: Vomiting

In brief

Delayed emesis following administration of carboplatin-based chemotherapy despite prophylaxis with standard antiemetic prophylaxis (5-HT3 and corticosteroid) remains a clinically significant and distressing problem for patients with cancer. The incidence of delayed emesis appears to be higher in women compared to men.

Key facts

Study ID

NCT00696280

Run by

Washington University School of Medicine

People needed

106

Starts

2006-11-01

Expected to finish

2009-11-01

Last updated by the study team

2013-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have newly diagnosed, histologically or cytologically proven cancer, and be scheduled to receive chemotherapy with carboplatin at AUC 5 or above.
• Patients should receive standard antiemetic prophylaxis prior to carboplatin administration, defined as 5-HT3 antagonist and dexamethasone. We will include only patients whose standard care includes treatment with a carboplatin-containing regimen and who are not being treated with aprepitant (Emend®).
• Age >= 18.
• After being informed of the treatment involved, patients must give written consent.
• Entry to this study is open to both men and women and to all racial and ethnic subgroups.

You may not qualify if…

• No prior cytotoxic chemotherapy within the last 5 years.
• Should not be pregnant.

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.